Drug Profile
Ondansetron - ADial Pharmaceuticals
Alternative Names: AD-04Latest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator University of Virginia
- Developer ADial Pharmaceuticals; University of Virginia
- Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Alcoholism
- No development reported Obesity; Opioid-related disorders; Smoking withdrawal
Most Recent Events
- 16 Apr 2024 Adial Pharmaceuticals has patent protection for ondansetron (AD 04) in combination with proprietary genetic diagnostic panel for the treatment of Alcohol use disorder and Opioid use disorder in USA
- 10 Apr 2024 Adverse events data from a phase III trial in Alcoholism released by Adial Pharmaceuticals
- 20 Feb 2024 ADial Pharmaceuticals has patent protection for AD 04 in USA